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a  b  s  t  r  a  c  t
Introduction  and  Objectives:  Non-alcoholic  fatty  liver  disease  (NAFLD)  is the  most  common  liver  dis-
ease  in  children  and  it is  more  prevalent  in Hispanic  males.  The  gender  differences  can  be explained  by
body  fat  distribution,  lifestyle,  or sex  hormone  metabolism.  We  evaluated  anthropometric  and  metabolic
differences  by  gender  in  children  with  and  without  NAFLD.
Methods:  We  included  194  participants  (eutrophic,  overweight,  and  individuals  with obesity).  The  pres-
ence  of NAFLD  was  determined  using  ultrasonography,  and  we  evaluated  the  association  between  this
disease  with  metabolic  and  anthropometric  variables  by  gender.
Results:  The  mean  age  was 10.64  ±  2.54 years.  The  frequency  of NAFLD  in  boys  was  24.51%  and  in  girls
was  11.96%  (OR  =  2.39;  95%CI  = 1.10–5.19;  p = 0.025).  For  girls,  NAFLD  was  significantly  associated  with
triglycerides  (p  =  0.012),  homeostatic  model  assessment  of  insulin  resistance  (HOMA-IR)  (p  =  0.048),  and
the visceral  adiposity  index  (VAI)  (p = 0.024).  The  variables  related  to NAFLD  in a  gender-specific  manner
were  body  mass  index  (BMI)  (p  =  0.001),  waist  circumference  (WC)  (p  <  0.001),  HDL  cholesterol  (p =  0.021),
alanine  aminotransferase  (ALT)  (p  <  0.001),  and  aspartate  aminotransferase  (AST)  (p =  0.002).
Conclusions:  In our study  NAFLD  is more  frequent  in boys,  only  ALT,  and  no  other  clinical or  metabolic
variables,  were  associated  with NAFLD  in  these  patients.  HOMA-IR,  VAI,  triglyceride  levels,  and  ALT  were
associated  with  NAFLD  only  in  girls.  The  ALT  cut-off  points  for  the  development  of NAFLD  in  our  study
were  28.5  U/L in  females  and  27.5 U/L in  males.  Our  findings  showed  that  NAFLD  should  be  intentionally
screened  in  patients  with  obesity,  particularly  in  boys.
©  2019  Fundación  Clı́nica  Médica  Sur, A.C. Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access
article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined by the pres-
ence of steatosis in more than 5% of hepatocytes in patients with
no history of alcohol consumption, no pharmacological treatment,
and no congenital disease [1,2]. NAFLD is the most frequent type
∗ Corresponding author at: Department of Human Genetics, Hospital General de
México “Dr Eduardo Liceaga”, Dr. Balmis 148, Col. Doctores, Delegación, Cuauhté-
moc, CP 06720, Ciudad de México, Mexico.
E-mail address: gngaribay@hotmail.com (G.N. Garibay-Nieto).
of liver disease in the pediatric population, with an overall preva-
lence of 7.6% and a cumulative prevalence of 34.2% in children with
obesity [3]. Epidemiological studies of NAFLD in Mexico show a
prevalence of 17.05% in asymptomatic adults and 12.6% in children
with a body mass index (BMI) >85th percentile (overweight and
obesity) [4,5].
Cross-sectional studies on humans and animal models have
reported a higher prevalence of NAFLD in the male gender. In the
pediatric population with obesity, the distribution by sex is 35.3%
in males and 21.8% in females [3]. Central obesity, insulin resis-
tance, dyslipidemia, Hispanic ethnicity, and the genetic variants
COL13A1, ADIPOQ, SAMM50, and PNPLA3 in Mexican Americans
https://doi.org/10.1016/j.aohep.2019.04.012
1665-2681/© 2019 Fundación Clı́nica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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and the Mexican-Mestizo population are the variables that are most
frequently associated with NAFLD [6–9].
Although a higher prevalence of NAFLD has been reported in
boys, gender-specific characteristics of this disorder have rarely
been explored. It has been proposed that the gender-specific dif-
ferences observed in the prevalence of NAFLD may  result from the
possible protective role of estrogens, which decrease the risk for
this disorder among females. Recent findings on the physiopathol-
ogy of NAFLD, evaluated from a gender-specific perspective, have
indicated that lipid metabolism and body fat distribution may play
a relevant role [10,11].
Pediatric patients are not frequently screened for NAFLD, and
thus, it is rarely identified, primarily because of the complexity
of the diagnosis [2,12]. This study aimed to evaluate the gender-
specific differences in the clinical and metabolic variables in a
pediatric population with NAFLD.
2. Methods
2.1. Study design
A cross-sectional comparative study was performed. Eutrophic,
overweight, and individuals with obesity and ranging in age from
6–18 years were consecutively included from January 2015 to
September 2016. Patients with overweight/obesity from the Child-
hood Obesity Clinic of the Hospital General de Mexico were invited
to participate, whereas eutrophic children were recruited from sur-
rounding schools. All patients included in this study were born
and raised in Mexico City and the suburban area. The local ethics
committee approved the protocol.
The participants were classified into the following groups,
according to the Centers for Disease Control and Prevention guide-
lines: eutrophic (BMI <85th percentile); overweight (BMI ≥85th
and <95th percentile); and obesity (BMI ≥95th percentile).
Patients with obesity that had a genetic or endocrine origin;
those with a previously known liver disease, diabetes or other
endocrinopathies; patients receiving a pharmacological treatment
that was able to modify lipid or carbohydrate metabolism; and
those who reported alcohol consumption were excluded.
Informed consent and assent were obtained from the partic-
ipants and their parent/legal guardian. All sensitive patient data
were protected in compliance with the Health Insurance Portabil-
ity and Accountability Act (HIPAA). A complete medical record was
documented for each participant.
The NAFLD diagnosis was determined by a liver ultrasound that
was performed by an expert ultrasonographer.
2.2. Anthropometric and metabolic evaluation
The clinical variables assessed were age, gender, weight, height,
BMI, waist circumference (WC), and sexual development stage.
A mechanical scale and a stadiometer were used to evaluate
weight and height. The measuring location for WC was the midway
point between the last costal cartilage and the anterosuperior iliac
crest. Pediatricians and pediatric endocrinologists appraised the
sexual status, according to the Tanner scale [13,14]. Arterial blood
pressure was measured from the right brachial artery using a man-
ual sphygmomanometer and special-sized pressure cuffs according
to the patient’s age, and the measurement was taken twice per
patient, with the patient in a sitting position.
We calculated the BMI  according to Quetelet’s equation [15].
Additionally, using the homeostatic model assessment of insulin
resistance (HOMA-IR), we calculated the insulin resistance index
[16].
A gender-specific visceral adiposity index (VAI) was calculated
using a formula that was previously proposed by our group for
pediatric populations, as follows:
Female VAI = WC/(−0.018[BMI2] + 3.3[BMI] + 7.86)
× (Triglycerides/0.91) × (1.42/HDL); and
Male VAI = WC/(−0.023[BMI2] + 3.83[BMI] + 0.65)
× (Triglycerides/0.76) × (1.37/HDL).
Metabolic variables were evaluated by obtaining venous blood
after the patients had fasted for 12 h. Enzymatic methods were per-
formed to measure glucose, aminotransferases, total cholesterol,
high density lipoprotein (HDL) cholesterol, low density lipopro-
tein (LDL) cholesterol, and triglycerides, using available commercial
kits. Insulin was  determined through chemiluminescence analysis.
Normal values were considered according to the North American
Society for Pediatric Gastroenterology, Hepatology and Nutrition
(NASPGHAN) and the Endocrine Society clinical practice guidelines
for NAFLD and pediatric obesity, respectively (alanine aminotrans-
ferase (ALT) <25 U/L in boys and <22 U/L for girls, HDL <40 mg/dL,
and triglycerides in patients 0–9 years <100 mg/dL and 10–19 years
<130 mg/dL) [17,18].
2.3. Ultrasonography
The NAFLD diagnosis was  performed using a B mode ultrasound
and a 1–4 mHz  curve transducer (Siemens Acuson S2000, Mountain
View, CA, USA), according a standardized protocol, by an expert
ultrasonographer who was blinded to the clinical and metabolic
conditions [19,20]. The kappa coefficient for intra-observer con-
cordance was 0.90. The steatosis condition was categorized as
present/not present, according to the hepatic tissue’s echogenicity,
in contrast to the adjunct right kidney’s parenchyma.
2.4. Statistical analyses
Descriptive and inferential statistics for numerical variables
were reported as the mean and standard deviation (SD), and the
percentages were used for categorical variables.
The inferential statistical analyses included a two-factor anal-
ysis of variance (ANOVA) for all anthropometric and metabolic
variables, considering the presence of NAFLD and gender as fac-
tor variables, and we ensured that the test assumptions were met.
The effect size was  calculated using Cohen’s f and was considered to
be as follows: >0.10 small; >0.25 medium; and >0.40 large [21,22].
Chi-squared tests and Fisher’s exact test were used to assess
categorical variables. Binary logistic regression evaluated the
association between NAFLD and BMI-Pc, ALT, aspartate amino-
transferase (AST), WC by gender, and triglycerides by sex [23].
The most relevant variables related to NAFLD were evaluated
using the receiver operating characteristics (ROC) curve analysis,
according to gender. The cut-off points, sensitivity, and specificity
were obtained for each variable [24,25].
All analyses were performed using the statistical software IBM
SPSS Statistics version 22.0 (IBM, Armonk, NY, USA). A p value of
<0.05 was  considered to be statistically significant.
3. Results
3.1. Descriptive statistics
A total of 194 patients (102 males and 92 females) were
recruited: 44 eutrophic, 38 overweight, and 112 with obesity. The
mean age of the participants was 10.64 ± 2.54 years.
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The overall NAFLD frequency in our study was 18.55%; it was
24.51% in boys and 11.96% in girls, which was significantly different
(OR = 2.39; 95%CI = 1.10–5.19; p = 0.025).
In the obesity group, the frequency was 29.46%: 32.8% in males
and 24.4% in females (OR = 1.51; 95%CI = 0.65–3.54; p = 0.340). We
found that 91.7% of the patients with a NAFLD were obese.
The participants’ demographic and anthropometric character-
istics (by gender) are shown in Table 1.
3.2. Inferential statistics
Differences in anthropometric and metabolic variables by gen-
der and the presence of NAFLD were assessed using two-factor
ANOVAs.
We found statistically significant differences between gender
and the presence of NAFLD for the following variables: triglycerides
(F(1,185) = 6.618, p = 0.012, f = 0.0895); insulin (F(1,174) = 6.197,
p = 0.021, f = 0.087); HOMA-IR (F(1,174) = 4.28, p = 0.048, f = 0.0895),
and VAI (F(1,185) = 5.47, p = 0.02, f = 0.0959). The combined effect
of the presence of NAFLD and gender was also evaluated for
all significant ANOVAs. The mean triglyceride concentration in
males with and without NAFLD and in females with and without
NAFLD were 132.32 ± 68.14, 120.85 ± 68.08, 210.18 ± 73.26, and
126.38 ± 74.13 mg/dL, respectively. When comparing differences in
triglyceride concentrations among the male and female patients
with and without this disease, we found that the mean triglyc-
eride concentration in female NAFLD patients was 77.86 mg/dL
higher than that in males. Similarly, in the group without NAFLD,
the triglyceride levels were higher in females compared to males,
with a mean difference of 5.53 mg/dL. The difference between the
differences was 70.993 (95%CI, 15.966–126.02, p = 0.012).
For insulin concentrations, the mean levels in males with and
without NAFLD and in females with and without this disorder
were 15.00 ± 5.69, 13.11 ± 6.75, 14.16 ± 12.08, and 14.92 ± 8.43
UI/L, respectively. In a mean comparison by gender and the
presence of NAFLD, male NAFLD patients had higher insulin con-
centrations compared to females, with a mean difference of 0.84
UI/L, whereas among patients without NAFLD, females had higher
insulin concentrations, with a mean difference of 1.81 UI/L. The dif-
ference between the differences was 7.357 (95%CI, 1.145–13.569,
p = 0.021).
The mean HOMA-IR levels in males with and without NAFLD and
in females with and without NAFLD were 3.24 ± 1.20, 2.56 ± 1.69,
5.20 ± 2.70, and 3.04 ± 1.99, respectively. In a mean comparison by
gender and the presence of NAFLD, in patients with NAFLD, females
had a higher mean HOMA-IR level compared to males, with a mean
difference of 1.96 points. Similarly, in patients without NAFLD, the
HOMA-IR level was  also higher in females than in males, with a
smaller mean difference of 0.48 points. The difference between the
differences was  1.471 (95%CI, 0.013–2.928, p = 0.048).
For VAI scores, the mean values in males with and without
NAFLD and in females with and without NAFLD were 2.87 ± 1.97,
2.57 ± 1.89, 4.30 ± 1.75, and 2.38 ± 1.66, respectively. In a mean
comparison by gender and the presence of NAFLD, in NAFLD
patients, the VAI scores were higher in females compared to males,
with a mean difference of 1.43 points. Similarly, among the partic-
ipants without NAFLD, females had higher VAI scores than males,
with a mean difference of 0.19 points. The difference between the
differences was 1.62 (95%CI, 0.215–3.024, p = 0.024) (Table 1 and
Fig. 1).
For the variables that did not demonstrate significant interac-
tions in factorial ANOVAs, the main effects were evaluated. The
following significant main effects from NAFLD were observed: for
BMI-Percentile (Pc) the mean was  97.48 ± 2.01 for patients with
NAFLD vs. 83.87 ± 22.52 for those without NAFLD (p = 0.001); for
WC, the mean was  86.82 ± 12.73 with NAFLD vs. 77.43 ± 13.47
without NAFLD (p < 0.001); for HDL cholesterol, the mean
was 37.53 ± 6.93 with NAFLD vs. 41.54 ± 10.21 without NAFLD
(p = 0.018); for ALT, the mean was 48.28 ± 21.98 with NAFLD vs.
22.22 ± 9.81 without NAFLD (p < 0.001); and for AST, the mean
was 36.14 ± 10.55 with NAFLD vs. 27.22 ± 6.58 without NAFLD
(p = 0.002; Table 1 and Fig. 1).
A binomial logistic regression was performed to ascertain the
effects of BMI  percentile, ALT, WC by gender, and triglycerides by
gender on the likelihood that participants would have NAFLD. The
logistic regression model was statistically significant (2(6) = 79.47,
p < 0.0001). The model explained 54.9% (Nagelkerke’s R2) of the
variance in NAFLD and correctly classified 81.2% of the cases. The
sensitivity of the model was 79%, and specificity was  90%; the pos-
itive predictive value was  53%, and the negative predictive value
was 97%. The model was then internally validated using the ROC
curve. The AUC value was  0.922 (95%CI = 0.877–0.966, p < 0.0001).
The only statistically significant variable was ALT (Table 2).
With the aim of evaluating the accuracy of the variables asso-
ciated with NAFLD by gender, we performed receiver-operating
characteristics (ROC) curve discrimination. For female participants
Table 1
Clinical and metabolic variables associated to NAFLD by gender in Mexican children.
Variables Male Female Gender NAFLD Gender and NAFLD
NAFLD n = 25 No NAFLDn = 77 NAFLD n = 11 No NAFLDn = 81 p p p
Age (years) 11.08 ± 2.04 10.26 ± 2.47 10.83 ± 3.27 10.85 ± 2.64 0.736 0.423 0.406
BMI  (percentile) 97.33 ± 2.19 85.85 ± 22.49 97.82 ± 1.56 81.72 ± 23.75 0.661 0.001 0.579
SBP  (mmHg) 99.17 ± 8.66 96.59 ± 8.92 100.91 ± 9.44 96.54 ± 8.83 0.493 0.083 0.461
DBP  (mmHg) 63.75 ± 6.25 62.03 ± 6.72 64.09 ± 7.36 61.91 ± 6.92 0.925 0.171 0.781
WC  (cm) 86.82 ± 12.73 77.57 ± 13.66 86.46 ± 14.51 75.89 ± 11.89 0.670 <0.001 0.388
Glucose  (mg/dL) 88.00 ± 5.88 88.38 ± 5.83 86.73 ± 7.17 86.23 ± 11.59 0.325 0.972 0.800
Triglycerides (mg/dL) 132.32 ± 68.14 120.85 ± 68.08 210.18 ± 73.26 126.38 ± 74.13 0.003* 0.001* 0.012
Total-C.  (mg/dL) 158.64 ± 26.64 163.62 ± 31.14 171.27 ± 30.24 154.86 ± 30.59 0.747 0.342 0.076
HDL-C  (mg/dL) 38.40 ± 6.72 42.61 ± 12.76 35.55 ± 7.30 40.78 ± 8.54 0.247 0.021 0.801
ALT  (IU/L) 49.0 ± 24.50 24.49 ± 10.94 46.64 ± 15.67 22.50 ± 24.57 0.173 <0.001** 0.662
AST  (IU/L) 36.16 ± 11.41 28.83 ± 7.10 36.09 ± 8.80 27.43 ± 16.66 0.768 0.002* 0.789
Insulin  (IU/L) 15.00 ± 5.69 13.11 ± 6.75 14.16 ± 12.08 14.92 ± 8.43 0.001* 0.001* 0.021
HOMA-IR 3.24 ± 1.20 2.56 ± 1.69 5.20 ± 2.70 3.04 ± 1.99 0.001* <0.001* 0.048
VAI  2.87 ± 1.97 2.57 ± 1.89 4.30 ± 1.75 2.38 ± 1.66 0.083 0.002* 0.024
Values expressed as means ± standard deviation.
NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC:  waist circumference; C: cholesterol; ALT:
alanine  aminotransferase; AST: aspartate aminotransferase; HOMA-IR: homeostatic model assessment; VAI: visceral adiposity index.
Effect size (f) = *0.10–0.24; **0.25–0.39.
Bold values are p values < 0.05.
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Fig. 1. Clinical and metabolic variables adjusted by gender and NAFLD condition in Mexican children.
On  X axis NAFLD condition is expressed. The values on Y axis express the estimated marginal means.
NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC:  waist circumference; Chol.: cholesterol;
ALT:  alanine aminotransferase; AST: aspartate aminotransferase; HOMA-IR: homeostatic model assessment – insulin resistance; VAI: visceral adiposity index.
Female: ; Male: .
with NAFLD, we found a significant AUC value for ALT, AST, WC,
HOMA-IR, triglycerides, and VAI values. Based on these results, and
by calculating the Youden index, we obtained the cut-off points for
these variables in males and females. In females, the optimal cut-off
points were as follows: ALT, 28.5 U/L (sensitivity 100%, speci-
ficity 89.2%); AST, 27.5 U/L (sensitivity 90.90%, specificity 62.20%);
WC,  79.5 cm (sensitivity 90.90%, specificity 64.90%); HOMA-IR,
2.08 (sensitivity 100%, specificity 44.6%); triglycerides, 128 mg/dL
(sensitivity 81.8%, specificity 69%); and VAI score, 2.33 (sensitivity
100%, specificity 63.5%).
In male patients, the only significant AUC value was  found for
ALT concentrations, and the cut-off point was 27.5 U/L (sensitivity
82.60%, specificity 80.60%; Fig. 2).
The presence of metabolic syndrome (MS) in females with and
without NAFLD was statistically significant, as shown by Fisher’s
exact test (OR = 9.019; 95%CI = 2.30–35.30; p = 0.002). However, in
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Table  2
Logistic regression predicting likelihood of NAFLD in Mexican children based on BMI, ALT, WC by gender and triglycerides by gender.
Variable B SE p OR 95%CI
Lower bound Upper bound
BMI  (percentile) 0.148 0.094 0.116 1.159 0.964 1.394
ALT  (IU/L) 0.100 0.020 <0.001 1.106 1.062 1.151
WC  by gender 0.014 0.013 0.281 1.014 0.988 1.041
Triglycerides by gender −0.008 0.006 0.230 0.992 0.980 1.005
NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; WC:  waist circumference; SE: standard
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Fig. 2. ROC curves for NAFLD by gender and ALT, AST, WC,  VAI, HOMA-IR and triglycerides.
(A)  Figure and table for female ROC curve. (B) Figure and table for male ROC curve.
NAFLD: non-alcoholic fatty liver disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; WC:  waist circumference; VAI: visceral adiposity index; HOMA-IR:
homeostatic model assessment – insulin resistance; AUC: area under curve; SE: standard error; CI: confidence interval; *p < 0.05.
ALT:  ; VAI: ; AST: ; triglycerides: ; WC:  ; HOMA-IR: .
males with and without NAFLD, there was no significant difference
(OR = 1.125; 95%CI = 0.36–3.51; p = 0.84).
4. Discussion
Our study results revealed gender-specific differences in
metabolic and anthropometric variables related to NAFLD. More-
over, we found evidence that the variables that were positively
associated with insulin resistance, such as insulinemia, HOMA-IR,
triglyceride concentration, and VAI scores, were also associated
with NAFLD in a gender-specific manner. For example, VAI, HOMA-
IR, and triglycerides were significantly higher in female patients
with NAFLD compared to males. However, in the regression anal-
ysis, the only variable that significantly predicted the presence of
NAFLD was ALT, which increased the risk of NAFLD by 10% for each
unit increment for both genders.
Mexico currently has one of the highest proportions peo-
ple with obesity, and consistent with the prevalence of NAFLD,
the frequency of NAFLD in our obesity group was  29.46%. The
development of NAFLD requires a complex interaction of multi-
factorial features such as genetic susceptibility and environmental
factors. Ramos-López et al. analyzed the pattern of dietary intake
in a Mexican population with and without liver disease, and they
found that both have a diet high in fat and cholesterol that lacks
polyunsaturated fatty acids and some micronutrients with antiox-
idant properties that have been associated with the development
of liver damage in the general population. The previous statements
could explain the relationship between pediatric patients and the
development of NAFLD through the influence of genetic variants of
risk, a sedentary lifestyle, and the Mexican obesogenic diet [26].
In our study, the frequency of NAFLD by gender was higher in
boys compared to girls, with a 2:1 ratio. Previous studies that were
included in an epidemiological meta-analysis of NAFLD showed
results similar to ours. Although the diagnostic methodologies used
in the studies included in this meta-analysis were heterogeneous,
the most frequently used method for diagnosing NAFLD was ultra-
sonography [3,11,27].
NAFLD is associated with various anthropometric and metabolic
factors, such as high BMI, ethnic group (with a higher prevalence
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in Asian and Hispanic patients), male gender, insulin resistance,
and dyslipidemia. BMI  has also been related to increased visceral
and profound subcutaneous adiposity, which are also considered
to be risk factors for NAFLD [28]. In our study, univariate analyses
performed by gender and the presence of NAFLD showed that in
males, the only variables that were significantly related to NAFLD
were ALT and those that indirectly reflect visceral adiposity (BMI
and WC). However, in females, NAFLD was also associated with a
higher BMI, WC,  and ALT, as well as higher insulin, HOMA-IR, and
VAI. Although in previous studies the variables involved in NAFLD
and insulin resistance are frequently reported, we found that there
is a gender-specific association between these variables and the
female population [2,6,7].
Our results also showed a significant association between
NAFLD and the BMI-Pc, WC,  HDL-cholesterol, and ALT concen-
tration, with no differences observed between the genders. This
finding is in accordance with that of Lonardo et al. and Singh et al.,
who reported that BMI, WC,  waist-to-height ratio, and waist-to-
hip ratio are gender-independent predicting factors for NAFLD in
adults [29,30].
ROC curve discrimination analysis by gender showed a sig-
nificant association between NAFLD and AST, ALT, triglycerides,
HOMA-IR, insulin, and VAI only in girls. In boys, the only variable
that behaved as a possible diagnostic biomarker was  ALT, confirm-
ing the gender-specific behavior. The means for ALT in both genders
from our study are aligned with the cut-off points that are recom-
mended by the SAFETY study and the Council for the Treatment of
Child Obesity published by the Endocrine Society [18,31].
In the last two decades, researchers worldwide have described
NAFLD as a condition with sexual dimorphism. Given the complex
multifactorial pathophysiology of NAFLD, research on the sexual
dimorphism inherent to this disease may  lead us to a better under-
standing of the pathophysiological processes that are involved
[11,29].
Women  tend to have more subcutaneous adipose tissue and
higher leptin levels, which, combined with estrogen production,
protects them from the accumulation of fatty tissue in the vis-
ceral compartment. In contrast, the distribution of adipose tissue
in males is primarily visceral, a condition that is associated with
insulin resistance and a greater influx of free fatty acids into the
portal venous system, thereby promoting NAFLD [10,11,32]. In our
study, we did not observe an association between NAFLD and any
of the factors related to insulin resistance in boys.
The influence of sex steroids on metabolic disturbances remains
an unanswered question because hyperandrogenic women as well
as men  with androgen deficiency tend to develop abdominal obe-
sity, insulin resistance, type 2 diabetes, and NAFLD, and they have
a higher cardiovascular risk [33].
Moreover, women with polycystic ovarian syndrome (PCOS)
have an increased prevalence of NAFLD compared to age and BMI-
paired controls (OR = 2.54; 95%CI = 2.19–2.95), and NAFLD-PCOS
women have an androgen bioavailability that increases indepen-
dently of BMI  and insulin resistance [34–36]. Conversely, androgen
deficiency in men  has been related to NAFLD, independent of other
known risk factors such as insulin resistance and visceral adipos-
ity [37]. These studies show that female androgen excess and male
androgen deficiency have similar metabolic phenotypes, showing
the complexity of androgens’ role in metabolism.
The variables in our study that were associated with NAFLD in
females are consistent with those observed in previous reports, and
these include insulin resistance, hypertriglyceridemia, and visceral
adiposity (evaluated as VAI and WC  in our study). Given that we
did not find an association between these variables and NAFLD in
males, we believe that it is possible that the pathophysiological
mechanisms in this population may  differ from those involved in
insulin resistance.
For lipid metabolism, studies performed in humans and in
animal models have shown an increased ability in females to
metabolize free fatty acids by lipolysis. However, males can have
prolonged de novo lipogenesis, which may  condition them for a
longer period of free fatty acid exposure and their associated dam-
age. These changes could help us to understand why men  are more
likely to develop NAFLD [38].
A study performed in the United Kingdom evaluated fatty acid
metabolism according to gender, and it showed that the beta-
oxidation during fasting in men  is less efficient compared to
women, and it also has longer lasting de novo lipogenesis. Both
phenomena may  promote esterification and storage of free fatty
acids in the liver, and consequently, stimulate the development of
NAFLD in the male population [38].
Experimental models have often shown that androgens and
estrogens are balanced in the modulation of hepatic lipid
metabolism. Zhang et al. suggested that the combined administra-
tion of selective androgen and estrogen receptor modulators could
be a potential treatment for patients with NAFLD [39]. Considering
that there is a fluctuation of estrogens or androgens in teenagers,
we attempted to evaluate the effect of these hormones by pubertal
stage; however, there were no differences between pubertal and
prepubertal patients.
The Metabolic syndrome (MS) is a critical factor that is related
to NAFLD, to the extent that NAFLD has been considered by many to
be the hepatic manifestation of this syndrome [40,41]. Concerning
the association of this disorder with MS,  it is relevant to say that
in our study, a statistically significant relationship was  observed
between NAFLD and MS  in females but not in males. The frequency
of NAFLD in patients with fewer than three criteria for MS  in our
study was  63.9%. These results are clinically relevant, considering
that in children with obesity, the presence of MS  is believed to be
the most important risk factor for the development of other comor-
bidities [42,43]. Our results contribute to the evidence that supports
considering each component of the MS  as a risk factor for NAFLD,
particularly hypertriglyceridemia (>110 mg/dL) [44]. Srinivas et al.
studied, from a gender perspective, the association of NAFLD with
MS component risk factors in an urban cohort, and they found that
the components related to this disorder in women were hyper-
glycemia and hypertriglyceridemia, whereas in men, only BMI  was
related (used as a criterion for MS  instead of WC)  [27]. In our study,
the only risk component among males was the indirect measure
of adiposity (WC), while in females, it was low HDL levels and
hypertriglyceridemia.
This study has some limitations. The most relevant limitation
is that the diagnosis of NAFLD was  not performed using the gold
standard (liver biopsy), because of the inherent risks related to
the procedure and ethical issues. We evaluated NAFLD using ultra-
sonography because of accessibility in our population.
According to our study, ALT, AST, WC,  triglycerides, HOMA-IR,
and VAI were only related to NAFLD in the female population. Logis-
tic regression showed that only ALT was predictive of NAFLD in
both genders. The ALT cut-off points for the development of NAFLD
in our study were 28.5 U/L (sensitivity 100%, specificity 89.2%)
in females and 27.5 U/L (82.60% sensitivity, 80.60% specificity) in
males. Although ALT was the only predictor for NAFLD in boys, it
does not have the same diagnostic efficiency as it does in females.
5. Conclusions
We  demonstrated that, although NAFLD is more frequent in
boys, only ALT, and no other clinical or metabolic variables, were
associated with NAFLD in these patients. HOMA-IR, VAI, triglyc-
erides levels, and ALT were associated with NAFLD only in girls.
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The ALT cut-off points for the development of NAFLD in our
study were 28.5 U/L in females and 27.5 U/L in males. Our results
suggest that we may  consider each MS  criterion individually as a
risk factor for developing NAFLD. Our findings showed that NAFLD
should be strongly suspected and that patients with obesity should
be intentionally screened for NAFLD, particularly boys.
Further research is required using non-invasive methods and
biomarkers that can help us to predict NAFLD in children and
teenagers.
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